Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)

  • End date
    May 16, 2023
  • participants needed
  • sponsor
    Boston Medical Center
Updated on 16 May 2022


Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge.

This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.

Condition Type 2 Diabetes Treated With Insulin
Treatment Insulin glargine, Novolog, Insulin FiAsp, standard carbohydrate diet
Clinical Study IdentifierNCT04460326
SponsorBoston Medical Center
Last Modified on16 May 2022


Yes No Not Sure

Inclusion Criteria

Males and female adult subjects admitted to Boston Medical Center to a medical or surgical floor
Consultation by the Inpatient Diabetes Service at Boston Medical Center is required prior to consent
Age ≥ 21 and <= 80 years
Diagnosed with type 2 diabetes at least 180 days prior to screening
Hyperglycemia during admission, as defined by a point of care and/or venous blood glucose ≥ 140 mg/dL
Prior to admission subjects must be using one of the following for outpatient diabetes
≥ 2 oral/injectable agents
One oral/injectable agent with a hemoglobin A1c of ≥ 8% within 3 months of enrollment
Patients who are expected to remain hospitalized for a minimum of 48 hours following
BMI <45 kg/m^2
CGM sensor placement
Subjects must have insulin glargine dosing planned at bedtime for the duration of the study period. Morning and afternoon dosing of insulin glargine are exclusionary

Exclusion Criteria

Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA)
Treatment or plan for treatment with glucocorticoids during the index hospitalization
Female patients who are pregnant (tested during hospitalization or screening) or breast-feeding during the hospitalization
Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery
Prior diagnosis of gastroparesis or cirrhosis
Clinically significant nausea and/or vomiting or unable to consume more than 30 grams of carbohydrate at each meal
Acute or chronic kidney disease with a serum creatinine of ≥ 2 mg/dL at the time of screening
Patients expected to receive nothing by mouth (NPO) for >24 hours
Use of continuous or intermittent enteral feeding or parenteral nutrition
Patient receiving aspirin and/or vitamin C during the hospitalization
Any mental condition rendering the subject unable to provide informed consent
Patients currently incarcerated
Patients using >1 unit/kg/day of insulin prior to admission
Insulin pump usage within the 2 weeks prior to or during admission
Patients currently using real-time continuous glucose monitoring (CGM) or personal flash glucose monitoring system (FGM)
Patients with a history of an allergy to any of the types of insulin or one of the excipients in the insulin used in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note